PP
CHRS icon

PDT Partners’s Coherus Oncology CHRS Stock Holding History

PDT Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-22,699
Closed -$164K – 870
2022
Q2 		$164K Buy
+22,699
New +$197K 0.01% 848
2022
Q1 		– Sell
-76,768
Closed -$1.23M – 957
2021
Q4 		$1.23M Buy
76,768
+63,209
+466% +$1.11M 0.09% 320
2021
Q3 		$218K Sell
13,559
-130,152
-91% -$1.91M 0.02% 673
2021
Q2 		$1.99M Sell
143,711
-12,110
-8% -$172K 0.13% 269
2021
Q1 		$2.28M Buy
155,821
+18,421
+13% +$313K 0.16% 245
2020
Q4 		$2.39M Sell
137,400
-190
-0.1% -$3.38K 0.16% 228
2020
Q3 		$2.52M Buy
+137,590
New +$2.56M 0.17% 193
2020
Q2 		– Sell
-26,774
Closed -$434K – 687
2020
Q1 		$434K Buy
26,774
+3,144
+13% +$58.1K 0.03% 407
2019
Q4 		$425K Buy
+23,630
New +$436K 0.03% 454

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

PDT Partners's CHRS Position: Q3 2022 in Review

PDT Partners sold out of Coherus Oncology (CHRS) in Q3 2022, closing a stake of 22,699 shares — an estimated $164K sold.

PDT Partners first reported a position in CHRS in Q4 2019 and held it in 9 quarters. The position peaked at $2.52M in Q3 2020. 174 funds tracked by Wall St. Rank hold CHRS as of Q3 2022.

  • PDT Partners reported no remaining Coherus Oncology position as of Q3 2022 after selling out during the quarter.
  • PDT Partners sold 22,699 Coherus Oncology shares in Q3 2022, an estimated $164K.
  • PDT Partners first reported a position in Coherus Oncology in Q4 2019 and held it in 9 quarters.
  • PDT Partners's Coherus Oncology position peaked at $2.52M in Q3 2020.
  • 174 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2022.

Based on PDT Partners's 13F filing for Q3 2022, filed 14 Nov 2022.